Insulin-like growth factor-I receptor expression regulates neuroblastoma metastasis to bone

Cancer Research

Volumn 66, Issue 13, 2006, Pages 6570-6578

  Van Golen, Cynthia M ^a   Schwab, Tracy S ^a   Kim, Bhumsoo ^a   Soules, Mary E ^a   Oh, Sang Su ^a   Fung, Kevin ^a   Van Golen, Kenneth L ^a   Feldman, Eva L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN C RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; BONE METASTASIS; BONE TISSUE; CARCINOGENICITY; CELL INTERACTION; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MICROENVIRONMENT; MOUSE; NEUROBLASTOMA; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL; TIBIA; TUMOR GROWTH;

ANIMALS; BONE NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; ENDOTHELIUM; FEMALE; HUMANS; MICE; MICE, NUDE; MICE, SCID; NEUROBLASTOMA; RECEPTOR, IGF TYPE 1; STROMAL CELLS;

EID: 33746143756     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1448     Document Type: Article

References (61)

1. Castleberry RP. Biology and treatment of neuroblastoma. Pediatr Clin North Am 1997;44:919-36.
2. Philip T. Overview of current treatment of neuroblastoma. Am J Pediatr Hematol Oncol 1992;14:97-102.
3. Karayalcin G, Paley C, Redner A, Shende A. Neuroblastoma. In: Lanzkowsky P, editor. Manual of pediatric hematology and oncology. New York: Churchill Livingstone; 1995. p. 419-36.
4. Foulstone E, Prince S, Zaccheo O, et al. Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol 2005;205:145-53.
5. Adams TE, Epa VC, Garrett TP, Ward CW. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 2000;57:1050-93.
6. Leinninger GM, Meyer GE, Feldman EL. IGFs and the nervous system. In: LeRoith D, Zumkeller W, Baxter R, editors. Insulin-like growth factors. http://www.eurekah. com/chapter.php?chapid=975&bookid=34&catid=19; 2003.
7. Kiess W, Koepf G, Christiansen H, Blum WF. Human neuroblastoma cells use either insulin-like growth factor-I or insulin-like growth factor-II in an autocrine pathway via the IGF-I receptor: variability of IGF, IGF binding protein (IGFBP) and IGF receptor gene expression and IGF and IGFBP secretion in human neuroblastoma cells in relation to cellular proliferation. Regul Pept 1997;72:19-29.
8. Liu X, Turbyville T, Fritz A, Whitesell L. Inhibition of insulin-like growth factor I receptor expression in neuroblastoma cells induces the regression of established tumors in mice. Cancer Res 1998;58:5432-8.
9. Meyer GE, Shelden E, Kim B, Feldman EL. Insulin-like growth factor I stimulates motility in human neuroblastoma cells. Oncogene 2001;20:7542-50.
10. Meyer A, van Golen CM, Kim B, van Golen KL, Feldman EL. Integrin expression regulates neuroblastoma attachment and migration. Neoplasia 2004;6:332-42.
11. Noujaim D, van Golen CM, van Golen KL, Grauman A, Feldman EL. N-Myc and Bcl-2 coexpression induces MMP-2 secretion and activation in human neuroblastoma cells. Oncogene 2002;21:4549-57.
12. Fidler IJ. The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revisited. Nat Rev Cancer 2003;3:453-8.
13. Kim B, van Golen C, Feldman EL. Insulin-like growth factor-I signaling in human neuroblastoma cells. Oncogene 2004;23:130-41.
14. Middleton J, Arnott N, Welsh S, Beresford J. Osteoblasts and osteoclasts in adult human osteophyte tissue express the mRNAs for insulin-like growth factors I and II and the type 1 IGF receptor. Bone 1995;16:287-93.
15. Singleton JR, Randolph AE, Feldman EL. Insulin-like growth factor I receptor prevents apotosis and enhances neuroblastoma tumorigenesis. Cancer Res 1996;56:4522-9.
16. Leventhal PS, Randolph AE, Vesbit TE, Schenone A, Windebank AJ, Feldman EL. Insulin-like growth factor-II as a paracrine growth factor in human neuroblastoma cells. Exp Cell Res 1995;221:179-86.
17. Cheng H-L, Feldman EL. Insulin-like growth factor-I (IGF-I) and IGF binding protein-5 in Schwann cell differentiation. J Cell Physiol 1997;171:161-7.
18. Chisalita SI, Arnqvist HJ. Insulin-like growth factor I receptors are more abundant than insulin receptors in human micro- and macrovascular endothelial cells. Am J Physiol Endocrinol Metab 2004;286:E896-901.
19. Cooper CR, Chay CH, Gendernalik JD, et al. Stromal factors involved in prostate carcinoma metastasis to bone. Cancer 2003;97:739-47.
20. Lundborg G, Dahlin L, Dohi D, Kanje M, Terada N. A new type of "bioartiflcial" nerve graft for bridging extended defects in nerves. J Hand Surg [Br] 1997;22:299-303.
21. Cooper CR, McLean L, Walsh M, et al. Preferential adhesion of prostate cancer cells to bone is mediated by binding to bone marrow endothelial cells as compared to extracellular matrix components in vitro. Clin Cancer Res 2000;6:4839-47.
22. Clemens TL, Rosen CJ. The insulin-like growth factor system and bone. In: LeRoith D, Zumkeller W, Baxter, RC, editors. Insulin-like growth factors. New York: Kluwer Academic/Plenum Publishers; 2003. p. 206-18.
23. Garcia-Echeverria C, Pearson MA, Marti A, et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004;:5:231-9.
24. Scotlandi K, Manara MC, Nicoletti G, et al. Antitumor activity of the insulin-like growth factor-1 receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005;65:3868-76.
25. Gotlieb WH, Bruchim I, Gu J, et al. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. Gynecol Oncol 2006;100:389-96.
26. Kim B, van Golen CM, Feldman EL. Insulin-like growth factor I induces preferential degradation of insulin receptor substrate-2 through the phosphatidylinositol 3-kinase pathway in human neuroblastoma cells. Endocrinology 2005;146:5350-7.
27. Sohara Y, Shimada H, Scadeng M, et al. Lytic bone lesions in human neuroblastoma xenograft involve osteoclast recruitment and are inhibited by bisphosphonate. Cancer Res 2003;63:3026-31.
28. Michigami T, Ihara-Watanabe M, Yamazaki M, Ozono K. Receptor activator of nuclear factor κB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res 2001;61:1637-44.
29. Tanabe M, Ohnuma N, Iwai J, et al. Bone marrow metastasis of neuroblastoma analyzed by MRI and its influence on prognosis. Med Pediatr Oncol 1995;24:292-9.
30. Leventhal PS, Russell JW, Feldman EL. IGFs and the nervous system. In: Rosenfeld R, Roberts CT, Jr., editors. Contemporary endocrinology: the IGF system. Totowa (New Jersey): Humana Press; 1999. p. 425-55.
31. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42.
32. Kakonen SM, Mundy GR. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 2003;97:834-9.
33. Keller ET, Zhang J, Cooper CR, et al. Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev 2001;20:333-49.
34. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997;16:2985-95.
35. Boyce BF, Yoneda T, Guise TA. Factors regulating the growth of metastatic cancer in bone. Endocr Relat Cancer 1999;6:333-47.
36. Jasty R, van Golen C, Lin HJ, et al. Bcl-2 and n-myc coexpression increases IGF-IR and features of malignant growth in neuroblastoma cell lines. Neoplasia 2001;3:304-13.
37. Khanna C, Jaboin JJ, Drakos E, Tsokos M, Thiele CJ. Biologically relevant orthotopic neuroblastoma xenograft models: primary adrenal tumor growth and spontaneous distant metastasis. In Vivo 2002;16:77-85.
38. Baserga R. Controlling IGF-receptor function: a possible strategy for tumor therapy. Trends Biotechnol 1996;14:150-2.
39. Draffin JE, McFarlane S, Hill A, Johnston PG, Waugh DJ. CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Res 2004;64:5702-11.
40. Asosingh K, Gunthert U, Bakkus MH, et al. In vivo induction of insulin-like growth factor-I receptor and CD44v6 confers homing and adhesion to murine multiple myeloma cells. Cancer Res 2000;60:3096-104.
41. Weber MH, Goltzman D, Kostenuik P, et al. Mechanisms of tumor metastasis to bone. Crit Rev Eukaryot Gene Expr 2000;10:281-302.
42. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004;5:221-30.
43. Warshamana-Greene GS, Litz J, Buchdunger E, Garcia-Echeverria C, Hofmann F, Krystal GW. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin Cancer Res 2005;11:1563-71.
44. Li Y, Tondravi M, Liu J, et al. Cortactin potentiates bone metastasis of breast cancer cells. Cancer Res 2001;61:6906-11.
45. 1 involvement in stromal cell-derived factor-1α-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion. Exp Cell Res 2004;294:571-80.
46. Roodman GD. Role of stromal-derived cytokines and growth factors in bone metastasis. Cancer 2003;97:733-8.
47. Asosingh K. Migration, adhesion and differentiation of malignant plasma cells in the 5T murine model of myeloma. Verb K Acad Geneeskd Belg 2003;65:127-34.
48. Qiang YW, Yao L, Tosato G, Rudikoff S. Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells. Blood 2004;103:301-8.
49. Puglianiello A, Germani D, Rossi P, Cianfarani S. IGF-I stimulates chemotaxis of human neuroblasts. Involvement of type 1 IGF receptor, IGF binding proteins, phosphatidylinositol-3 kinase pathway and plasmin system. J Endocrinol 2000;165:123-31.
50. Ritchie CK, Andrews LR, Thomas KG, Tindall DJ, Fitzpatrick LA. The effects of growth factors associated with osteoblasts on prostate carcinoma proliferation and chemotaxis: implications for the development of metastatic disease. Endocrinology 1997;138:1145-50.
51. Doerr ME, Jones JI. The roles of integrins and extracellular matrix proteins in the insulin-like growth factor I-stimulated chemotaxis of human breast cancer cells. J Biol Chem 1996;271:2443-7.
52. Yoneda T, Williams PJ, Hiraga T, Niewolna M, Nishimura R. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner Res 2001;16:1486-95.
53. Anderson KC. Moving disease biology from the lab to the clinic. Cancer 2003;97:796-801.
54. Sikes RA, Nicholson BE, Koeneman KS, et al. Cellular interactions in the tropism of prostate cancer to bone. Int J Cancer 2004;110:497-503.
55. Russell HV, Hicks J, Okcu MF, Nuchtern JG. CXCR4 expression in neuroblastoma primary tumors is associated with clinical presentation of bone and bone marrow metastases. J Pediatr Surg 2004;39:1506-11.
56. Geminder H, Sagi-Assif O, Goldberg L, et al. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J Immunol 2001;167:4747-57.
57. Goya M, Miyamoto S, Nagai K, et al. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res 2004;64:6252-8.
58. Goltzman D. Osteolysis and cancer. J Clin Invest 2001;107:1219-20.
59. Sohara Y, Shimada H, Minkin C, Erdreich-Epstein A, Nolta JA, DeClerck YA. Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells. Cancer Res 2005;65:1129-35.
60. Rubin J, Ackert-Bicknell CL, Zhu L, et al. IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-κB ligand in vitro and OPG in vivo. J Clin Endocrinol Metab 2002;87:4273-9.
61. Garber K. IGF-I: old growth factor shines as new drug target. J Natl Cancer Inst 2005;97:790-2.